Virotherapy of peritoneal carcinomatosis
UM Lauer, M Zimmermann, J Sturm, S Berchtold, U Koppenhöfer, M Bitzer, NP Malek, J Glatzle, A Königsrainer, R Möhle, F Fend, C Pfannenberg, T Auth, T Yu, AA Szalay · Zeitschrift für Gastroenterologie · 2013 · Heft 08
Bibliografische Angaben
Zusammenfassung
Introduction: Peritoneal carcinomatosis (PC) is one of the most aggressive and difficult-to-treat tumor entities. We are currently recruiting patients with PC being refractory to any conventional therapy in a monocentric phase I/II study (NCT01443260) designed to assess safety, MTD, and anti-tumor activity of GL-ONC1, a recombinant Vaccinia virus (VACV) genetically engineered to selectively replicate in and destroy cancer cells. Methods: GL-ONC1 is administered intraperitoneally up to 4 times every 28 days under a standard 3+3 dose escalation design. Safety is assessed using CTCAEv4.0. Anti-tumor activity is det…
